Some patients may remain at the 1.7 mg dose if the 2.4 mg dose is not tolerated
Woodard K, Louque L, Hsia DS
Tirzepatide (Zepbound and Mounjaro) targets two such hormones, known as GLP-1 and GIP, while semaglutide (Ozempic and Wegovy) targets GLP-1 alone Originally meant to treat diabetes, the drugs surged in popularity after the Food and Drug Administration approved them for weight loss in 2021
Yes, it may increase during dose escalation, which is why GLP-1 medicines are introduced gradually
At the end of the day, if youre trying to lose weight, consult a doctor before trying a new strategy or supplementno matter how promising it appears
Proper peptide storage practices minimize this risk